What is the official ID of this bill?
The official print number for this legislation is S 3080.
Equal Cancer Drug Costs: Oral vs. Intravenous
New rules aim to ensure that insurance plans treat oral cancer medications the same as intravenous or injected drugs when it comes to patient out-of-pocket costs. This means your deductibles, co-insurance, or co-payments for oral anticancer drugs will not be higher than for medications administered by a healthcare provider. The act seeks to reduce financial burdens for cancer patients, improving access to necessary treatments.
Key points
Insurers cannot impose higher cost-sharing for oral cancer drugs than for intravenously administered or injected ones.
Prohibits increasing overall out-of-pocket costs for cancer medications or reclassifying benefits to circumvent new rules.
The act does not require replacing intravenous drugs with oral ones, nor does it prevent insurers from requiring prior authorization for chemotherapy.
Provisions apply to plan years beginning on or after January 1, 2022.
A study will be conducted within two years to assess the act's impact on out-of-pocket costs for oral medications.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.